Venetoclax

Venetoclax is a targeted oral cancer medication used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. It works by inhibiting the BCL-2 protein, which helps cancer cells die naturally. It is grouped under the following drug class(es): Antineoplastic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Venclexta, Venclyxto and Venetoclaxum. Its PubChem CID is 49846579.

CAS No 1257044-40-8
Molecular Formula C45H50ClN7O7S
Molecular Weight 868.4 g/mol
Synonyms 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

Frequently Asked Questions